With public market capitalizations sagging and venture capitalists hesitant to commit new capital, large publicly traded medical device companies were expected to feast on capital-starved device start-ups during this recession. However, this clearly hasn’t happened. If not for the $1.25 billion spent by Medtronic PLC for Medtronic Ablation Frontiers LLC, Medtronic CoreValve LLC and Ventor Technologies Ltd., the strategic acquisition market would be just as bleak as the market for initial public offerings of stock. [See Deal][See Deal][See Deal]
But the business development offices at Johnson & Johnson, St. Jude Medical Inc. and others have been busy....
Welcome to Scrip
Create an account to read this article
Already a subscriber?